Experienced in Myelofibrosis

Dr. Abhimanyu Ghose

Hematology | Oncology
Honorhealth Ambulatory
10510 N 92nd St, 
Scottsdale, AZ 
Accepting New Patients
Offers Telehealth
Experienced in Myelofibrosis
Honorhealth Ambulatory
10510 N 92nd St, 
Scottsdale, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Abhimanyu Ghose is a Hematologist and an Oncologist in Scottsdale, Arizona. Dr. Ghose is rated as an Experienced provider by MediFind in the treatment of Myelofibrosis. His top areas of expertise are Adult Soft Tissue Sarcoma, Bone Tumor, Familial Prostate Cancer, and Familial Colorectal Cancer. Dr. Ghose is currently accepting new patients.

His clinical research consists of co-authoring 16 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Myelofibrosis.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
Mercy Gilbert Medical Center
Honor Health John C. Lincoln Medical Center
Chandler Regional Medical Center
Languages Spoken
English
Bengali
Hindi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EMI Health
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MercyCare
  • EPO
  • HMO
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

HONORHEALTH AMBULATORY
10510 N 92nd St, Scottsdale, AZ 85258
Other Locations
HONORHEALTH AMBULATORY
7695 S Research Dr, Tempe, AZ 85284

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2024
Intervention Type: Biological, Drug
Study Drugs: Tomivosertib, Pembrolizumab
Study Phase: Phase 2
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Drugs: Itacitinib, Ruxolitinib
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

16 Total Publications

Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States.
Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States.
Journal: Journal of gastrointestinal oncology
Published: January 13, 2017
Similar Doctors
Distinguished in Myelofibrosis
Dr. John K. Camoriano
Hematology Oncology | Oncology | Hematology
Distinguished in Myelofibrosis
Dr. John K. Camoriano
Hematology Oncology | Oncology | Hematology

Mayo Clinic Arizona

5777 E Mayo Blvd, Mayo Clinic Hospital, 
Phoenix, AZ 
 (6.9 miles away)
800-603-0558
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Camoriano is a Hematologist Oncology specialist and an Oncologist in Phoenix, Arizona. Dr. Camoriano is rated as a Distinguished provider by MediFind in the treatment of Myelofibrosis. His top areas of expertise are Myelofibrosis, Polycythemia Vera, Myeloproliferative Neoplasms (MPN), Thrombocytopenia, and Bone Marrow Aspiration. Dr. Camoriano is currently accepting new patients.

Distinguished in Myelofibrosis
Dr. Ryan S. Robetorye
Hematology
Distinguished in Myelofibrosis
Dr. Ryan S. Robetorye
Hematology

Mayo Clinic Arizona

5779 E Mayo Blvd, Speciality Building, 
Phoenix, AZ 
 (6.9 miles away)
480-301-8000
Languages Spoken:
English
See accepted insurances

Ryan Robetorye is a Hematologist in Phoenix, Arizona. Dr. Robetorye is rated as a Distinguished provider by MediFind in the treatment of Myelofibrosis. His top areas of expertise are Acute Myelomonocytic Leukemia, Chronic B-Cell Leukemia (CBCL), Richter Syndrome, and Chronic Lymphocytic Leukemia (CLL).

Distinguished in Myelofibrosis
Dr. Nandita Khera
Hematology Oncology | Hematology | Oncology
Distinguished in Myelofibrosis
Dr. Nandita Khera
Hematology Oncology | Hematology | Oncology

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
 (5.1 miles away)
480-301-8000
Languages Spoken:
English, Hindi
See accepted insurances
Offers Telehealth

Nandita Khera is a Hematologist Oncology specialist and a Hematologist in Scottsdale, Arizona. Dr. Khera is rated as a Distinguished provider by MediFind in the treatment of Myelofibrosis. Her top areas of expertise are Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ghose's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 127 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile